Director/PDMR Shareholding

RNS Number : 3415L

Venn Life Sciences Holdings PLC

21 December 2018

 

21 December 2018

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Director/PDMR  Dealings

Venn Life Sciences ("Venn") an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations announces that Michael Ryan, Senior Independent Director, has sold 138,672 ordinary shares in Venn at a price of 1.9p per share, in order to crystalise certain capital tax losses. Following this sale, Mr Ryan remains interested in 134,586 ordinary shares in the Company.

Further information is disclosed below pursuant to Article 19(3) of the Market Abuse Regulation.  

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Michael Ryan
2	Reason for the notification
a)	Position/status	Senior Independent Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) b)	Name LEI code	Venn Life Science Holdings PLC 213800VT5KBM7JLIV118
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of nominal value of 0.1 pence each
	Identification code	ISIN GB00B9275X97
b)	Nature of the transaction	Sale of ordinary shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1.9p per share	138,672
d)	Aggregated information
	- Aggregated volume	N/A - single transaction
	- Price
e)	Date of the transaction	21 December 2018
f)	Place of the transaction	London Stock Exchange (AIM)

Enquiries:

Venn Life Sciences Holdings Plc
Tony Richardson, Chief Executive Officer	Tel: [phone]
Cenkos (Nominated Advisor and Co-Broker) Mark Connelly/Steve Cox (Corporate Finance)	Tel: [phone]
Davy (ESM Adviser and Co-Broker)
Fergal Meegan / Matthew de Vere White (Corporate Finance)		Tel: [phone]

About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

Further information in relation to Venn Life Sciences www.vennlifesciences.com

 

END

 

 

DSHLLFFRFRLLFIT